Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0
Links:
The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on An…
https://acrabstracts.org/abstract/the-efficacy-and-safety-of-telitacicept-follo…
16-11-2024